Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B disease through two seasons has been approved by Hong Kong Department of Health in April 2024 ; it has also been approved by Instituto para a Supervisão e Administração Farmacêutica in Macau in January 2024 The bivalent vaccine is expected to be available in Macau by June 2024 , followed by Hong Kong by August 2024 HONG KONG and MACAU May 8, 2024 /PRNewswire/ -- Pfizer Inc. announced today that the Hong Kong Department of Health (DH) has granted marketing authorization for the company's bivalent RSV prefusion F (RSVpreF) vaccine to fight against lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in individuals aged 60 years and older, and infants from birth up to six months of age through the active immunization of pregnant individuals Pfizer Inc. is currently the only company with an RSV vaccine suitable for use in both older adults and pregnant individuals. RSV is a con
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Moderna wins patent case in Europe against Pfizer, BioNTech over COVID shot [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pfizer Stock: Rebound Has Started (Technical Analysis) [Seeking Alpha]Seeking Alpha
- Active Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield [Seeking Alpha]Seeking Alpha
- 2 Top Growth Stocks Down 24% and 50% to Buy With $100 [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/9/24 - Form S-8
- PFE's page on the SEC website